Horizon Pharma (HZNP) Lifted to “Hold” at BidaskClub
Horizon Pharma (NASDAQ:HZNP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.
Several other equities analysts also recently weighed in on HZNP. Jefferies Group raised their target price on shares of Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. UBS Group set a $20.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a report on Thursday, November 30th. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a report on Friday, December 1st. ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Mizuho upgraded shares of Horizon Pharma from a “neutral” rating to a “buy” rating and raised their target price for the company from $12.00 to $18.00 in a report on Friday, January 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $18.64.
Horizon Pharma (NASDAQ HZNP) traded up $0.66 during trading hours on Friday, reaching $15.44. 1,860,000 shares of the company’s stock traded hands, compared to its average volume of 1,860,000. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $16.40. The stock has a market cap of $2,530.00, a P/E ratio of -6.13, a P/E/G ratio of 0.68 and a beta of 1.34.
Hedge funds and other institutional investors have recently modified their holdings of the company. Advantage Investment Management LLC grew its holdings in shares of Horizon Pharma by 164.8% during the third quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,900 shares in the last quarter. Brown Advisory Inc. purchased a new stake in shares of Horizon Pharma during the third quarter worth about $145,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Horizon Pharma during the fourth quarter worth about $160,000. K2 Principal Fund L.P. grew its holdings in shares of Horizon Pharma by 126.1% during the fourth quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 53,574 shares in the last quarter. Finally, Zeke Capital Advisors LLC purchased a new stake in shares of Horizon Pharma during the fourth quarter worth about $167,000. Institutional investors and hedge funds own 84.39% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/horizon-pharma-hznp-lifted-to-hold-at-bidaskclub/1904310.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.